Clinical Trials
13 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT00471432 2023-08-04
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT00937417 2017-04-24
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Phase 1 Withdrawn
NCT00003565 2016-07-14
Docetaxel in Treating Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01172028 2015-12-03
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
University of Arizona
Phase 1 Completed
NCT00539968 2015-02-05
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00511576 2015-01-08
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT00014456 2013-08-28
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00003103 2013-07-03
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00059943 2013-01-16
Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00288444 2012-12-18
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Emory University
Phase 1 Terminated
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00069160 2012-10-12
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed